video still
Astellas Pharma
A keiretsu-backed Japanese pharma merger that bought its way into oncology — but couldn’t fix its own dosing labels.
Medicine
The practice of intervening in a body, with evidence arriving late.
- 15
- in business
- 10:22
- average
- 156 min
- in total
- 104
- across the network
All briefs
video still
AstraZeneca
AstraZeneca is not a British company — it is a 1999 merger with no disclosed financials, no stated cost model, and no evidence of how it actually delivers value beyond its own description.
video still
Aurobindo Pharma
Aurobindo Pharma doesn’t sell cures—it sells compliance at scale.
video still
Biogen
Cesar Milstein · 1978
Biogen is a neurology-focused biotech that built scale via acquisition, not foundational science — and César Milstein, whose hybridoma work underpins modern antibody therapeutics, has no documented relationship to the company.
video still
Bristol Myers Squibb
A 1989 merger of two penicillin-makers became a US-revenue monoculture built on seven drugs — not science, but scale.
video still
Cipla
Cipla built scale before science—and still runs on that engine.
video still
Daiichi Sankyo
A merger-born giant that bought its way into oncology — but still answers to US prosecutors for kickbacks.
video still
Eisai (company)
Eisai didn’t build a global pharma business — it bought one, piece by piece, while outsourcing its biggest launches.
video still
Genmab
Jan van de Winkel · 1998
Genmab is a platform biotech — not a drug developer — built around two licensed and proprietary antibody generation methods. Its value is in reducing discovery risk and time, not in owning clinical or commercial outcomes.
video still
Johnson & Johnson
Robert Wood Johnson · 1886
Johnson & Johnson began as a vertically integrated supplier of standardised, sterile medical consumables — selling trust, training, and readiness, not cures.
video still
Lupin (company)
Lupin built its business on public health contracts — not disruption, not patents, not venture capital.
video still
Novo Nordisk
Novo Nordisk is not a biotech disruptor — it is the institutional heir to Denmark’s 1920s insulin labs, built on merger, not molecule.
video still
Novartis
A merger born of necessity, not vision — Novartis was built to survive, not invent.
video still
Roche
Roche isn’t a biotech pioneer — it’s a precision acquirer that turns diagnostics and drugs into a single revenue stream.
video still
Sanofi
In 2004, Sanofi didn’t innovate—it absorbed.